

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

**VOLUNTARY ANNOUNCEMENT
ENTERING INTO STRATEGIC RESEARCH COLLABORATION
AGREEMENT WITH ASTRAZENECA**

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group has entered into an strategic research collaboration agreement (the “**Agreement**”) with the global biopharmaceutical leader AstraZeneca for the discovery and development of novel oral small molecule candidates utilising the Group’s AI-driven, dual-engine efficient drug discovery platform. This platform uses AI technology to analyse the binding patterns of target proteins with existing compound molecules and conduct targeted optimisation, with the aim of selecting highly effective small molecules with excellent developability.

Under the terms of the Agreement, the Group agreed to discover pre-clinical candidates (“**PCC**”) for multiple targets as selected by AstraZeneca with potential to treat diseases across indications, including a pre-clinical small molecule oral therapy for immunological diseases.

For each PCC program, AstraZeneca shall have rights to exercise the option for an exclusive license for development, manufacturing and commercialisation worldwide. The Group will receive an upfront payment of US\$110 million, and is also eligible to receive up to US\$1,620 million in potential development milestone payments and up to US\$3,600 million in potential sales milestone payments, plus potential single digit royalties based on annual net sales of the products.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 13 June 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.